Pair page
Matrixyl with Nonapeptide-1
Mechanism-tag overlap and published literature for Matrixyl and Nonapeptide-1, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Matrixyl unique
collagen-signal-peptide
Shared
cosmetic-peptide
Nonapeptide-1 unique
brighteningmc1r-antagonist
Quick facts
Matrixyl
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient (not a drug)
WADAN/A (topical cosmetic)
Nonapeptide-1
RouteTopical (cosmetic)
Half-lifeNot listed
FDA statusCosmetic ingredient
WADANot applicable (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Matrixyl | Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570099. (UCSF Dermatology systematic review of topical peptides for aged skin, including Pal-KTTKS signal-peptide class.) PMID 19570099 | systematic review |
| 2010 | Matrixyl | Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescri… PMID 20374604 | human trial |
| 2024 | Matrixyl | Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. PMID: 38399273. (Liposomal delivery system for Pal-KTTKS… PMID 38399273 | preclinical, in vitro |
| 2017 | Matrixyl | Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID: 30603464. (CTGF / α-SMA modulation and fibrobl… PMID 30603464 | preclinical, in vitro |
| 2014 | Matrixyl | Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. PMID: 25143811. (Demonstrates palmitoylation as stability and permeation enhancer relative to un… PMID 25143811 | preclinical, in vitro |
| 2013 | Matrixyl | Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. PMID: 23320752. (Direct fibroblast collagen-production dose-response for Pal-KTTKS linked to critical-aggregation-con… PMID 23320752 | preclinical, in vitro |
| 2019 | Matrixyl | Tałałaj U, Uscinowicz P, Bruzgo I, Surazynski A, Zareba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019;24(20):3698. PMID: 31618846. (Structure-activity series of KTTKS analogues with acetyl / lipoyl / pa… PMID 31618846 | mechanism / discovery |
| 2019 | Matrixyl | Mortazavi SM, Kobarfard F, Maibach HI, Moghimi HR. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. J Cosmet Sci. 2019;70(6):299-312. PMID: 31829923. (Physicochemical characterization of palmitoyl conjugation effects on… PMID 31829923 | mechanism / discovery |
| 2007 | Matrixyl | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Updated Dermatologic Therapy review of signal, neurotransmitter-affecting, and carrier peptides.) PMID 18045359 | review |
| 2005 | Matrixyl | Osborne R, Mullins L, Jarrold B, Lintner K. In vitro skin structure benefits with a new antiaging peptide, Pal-KT. J Am Acad Dermatol. 2005;52(3 Suppl):P34. (AAD-meeting abstract on Pal-KT / Pal-KTTKS cosmetic evaluation; Procter & Gamble / Sederma collaboration.) | industry documentation |
| 2009 | Matrixyl | Trookman NS, Rizer RL, Ford R, Ho E, Gotz V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J Clin Aesthet Dermatol. 2009;2(3):38-43. PMID: 20729942. (8-week topical treatment clinical study including palmitoyl pentapeptide active… PMID 20729942 | research article |
| 2005 | Matrixyl | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The 93-subject 12-week split-face vehicle-controlled RCT of 3 ppm Pa… PMID 18492182 | research article |
| 2019 | Nonapeptide-1 | Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: A systematic review of randomized controlled trials. J Drugs Dermatol. 2019;18(11):1156-1163. PMID: 31741361. (Systematic review of RCT evidence for topical melasma treatments — the evidence-quality benchmark that no… PMID 31741361 | systematic review |
| 2009 | Nonapeptide-1 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663111. (Decapeptide-12 melasma pilot — the closest published pep… PMID 19663111 | human trial |
| 2012 | Nonapeptide-1 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527433. (Follow-up decapeptide-12 melasma open-label trial — the peptide brightener with the most published independent… PMID 22527433 | human pilot |
| 1999 | Nonapeptide-1 | Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C. The melanocortin-1 receptor and human pigmentation. Ann N Y Acad Sci. 1999;885:117-133. PMID: 10816645. (Review of MC1R biology in human cutaneous pigmentation.) PMID 10816645 | human study |
| 1995 | Nonapeptide-1 | Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. The expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2), the silver protein, and a melanogenic inhibitor in human melanoma cells of differing melanogenic activities. Pig… PMID 7659683 | human study |
| 1995 | Nonapeptide-1 | Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ. Nle4DPhe7 alpha-melanocyte-stimulating hormone increases the eumelanin:phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol. 1995;104(1):83-85. PMID: 7798647. (NDP-MSH / melanotan-I demonstration of agonist-driven eume… PMID 7798647 | preclinical, in vitro |
| 2012 | Nonapeptide-1 | Kadekaro AL, Chen J, Yang J, Chen S, Jameson J, Swope VB, Cheng T, Kadakia M, Abdel-Malek Z. Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes. Mol Cancer Res. 2012;10(6):778-786. PMID: 22622028. (Docum… PMID 22622028 | mechanism / discovery |
| 1996 | Nonapeptide-1 | Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 1996;137(5):1627-1633. PMID: 8612494. (Original characterization of α-MSH / ACT… PMID 8612494 | mechanism / discovery |
| 1994 | Nonapeptide-1 | Kobayashi T, Urabe K, Winder A, Jiménez-Cervantes C, Imokawa G, Brewington T, Solano F, García-Borrón JC, Hearing VJ. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J. 1994;13(24):5818-5825. PMID: 7813420. (Functional characterizat… PMID 7813420 | mechanism / discovery |
| 1992 | Nonapeptide-1 | Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992;11(2):519-526. PMID: 1537333. (Original characterization of TRP-2 / DCT as the dopachrome tautomerase — part… PMID 1537333 | mechanism / discovery |
| 2025 | Nonapeptide-1 | Austin E, Geisler AN, Nguyen J, Kohli I, Hamzavi I, Lim HW, Jagdeo J. Peptide design for enhanced anti-melanogenesis: Optimizing molecular weight, polarity, and cyclization. Int J Cosmet Sci. 2025;47(1):37-52. PMID: 39896936. (Recent review of anti-melanogenic peptide design pri… PMID 39896936 | review |
| 2021 | Nonapeptide-1 | Herraiz C, Martínez-Vicente I, Maresca V. The α-melanocyte-stimulating hormone/melanocortin-1 receptor interaction: A driver of pleiotropic effects beyond pigmentation. Pigment Cell Melanoma Res. 2021;34(4):748-761. PMID: 33884776. (Current comprehensive review of α-MSH/MC1R sig… PMID 33884776 | review |
Related pair pages
More research context
Frequently asked
Have Matrixyl and Nonapeptide-1 been studied together?
No co-administration studies between Matrixyl and Nonapeptide-1 are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Matrixyl and Nonapeptide-1 share?
Matrixyl and Nonapeptide-1 share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Matrixyl and Nonapeptide-1?
Matrixyl: Cosmetic ingredient (not a drug). Nonapeptide-1: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Matrixyl and Nonapeptide-1?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Matrixyl profile and the Nonapeptide-1 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026